Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Long-Term Investments (2023 - 2025)

Telix Pharmaceuticals has reported Long-Term Investments over the past 3 years, most recently at $37.1 million for Q4 2025.

  • Quarterly Long-Term Investments rose 1.12% to $37.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.1 million through Dec 2025, up 1.12% year-over-year, with the annual reading at $37.1 million for FY2025, 6.76% up from the prior year.
  • Long-Term Investments was $37.1 million for Q4 2025 at Telix Pharmaceuticals, up from $36.7 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $37.1 million in Q4 2025 and troughed at $8.0 million in Q4 2023.
  • The 3-year median for Long-Term Investments is $36.7 million (2024), against an average of $27.3 million.
  • Year-over-year, Long-Term Investments surged 359.61% in 2024 and then grew 1.12% in 2025.
  • A 3-year view of Long-Term Investments shows it stood at $8.0 million in 2023, then surged by 359.61% to $36.7 million in 2024, then increased by 1.12% to $37.1 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Long-Term Investments are $37.1 million (Q4 2025), $36.7 million (Q4 2024), and $8.0 million (Q4 2023).